205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
Year: 2022
Type: article
Source: Annals of Oncology
Authors: A. Cortés Salgado, J.M. Perez Garcia, S.P. Cortez Castedo, M. Gion Cortes, S. Morales Murillo, I. Blancas López-Barajas, S. Blanch, I. Calvo Plaza, N. Diaz Fernandez, F. Marmé, A. Martinez Bueno, M.T. Taberner Bonastre, M. De Laurentiis, M. Ruiz Borrego, P. Schmid, V. Guarneri, J. Gligorov, M. Sampayo-Cordero, A. Llombart Cussac, J. Cortés
Institutions: Hospital Universitario Ramón y Cajal, Hospital Universitari Arnau de Vilanova, Fundación Instituto Valenciano de Oncología, MD Anderson Cancer Center Madrid, Hospital General Universitario de Alicante Doctor Balmis, University Medical Centre Mannheim, Hospital Universitario Dexeus, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Hospital Universitario Virgen del Rocío, Queen Mary University of London, Barts Cancer Institute, University of Padua, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Hôpital Tenon, MedSIR (Spain), Hospital Arnau de Vilanova
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4228997367